Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 17/20 | 0.62 |
| ▸ | HTR1A | P08908 | 8/20 | 0.62 |
| ▸ | DRD2 | P14416 | 4/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | DRD5 | P21918 | 3/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15396975 | 0.98 | HTR7 (0.63) | HTR7HTR1ADRD2DRD3DRD5 | |
| SCHEMBL23339326 | 0.98 | HTR7 (0.63) | HTR7HTR1ADRD2DRD3DRD5 | |
| SCHEMBL7476444 | 0.95 | DRD2 (0.63) | HTR7HTR1ADRD2DRD3DRD5 | |
| SCHEMBL8240109 | 0.88 | HTR7 (0.57) | HTR7HTR1ADRD2DRD3DRD5 | |
| SCHEMBL7708386 | 0.86 | HTR7 (0.51) | HTR7HTR1ADRD2DRD3DRD5 | |
| SCHEMBL3374155 | 0.86 | DRD2 (0.77) | DRD2DRD3CHRM2CHRM4CHRM5 | |
| SCHEMBL29643502 | 0.85 | ALDH1A1 (0.54) | HTR7HTR1ADRD2DRD3DRD5 | |
| SCHEMBL27474717 | 0.85 | ALDH1A1 (0.54) | HTR7HTR1ADRD2DRD3DRD5 | |
| SCHEMBL590887 | 0.85 | ALDH1A1 (0.54) | HTR7HTR1ADRD2DRD3DRD5 | |
| SCHEMBL344854 | 0.85 | ALDH1A1 (0.54) | HTR7HTR1ADRD2DRD3DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20210309647-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-10-07 | — | — | US | disclosed |
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| US-20190152960-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-05-23 | — | — | US | disclosed |
| CN-103421012-A | Method for preparing tricarbazole material from aryl indolone in one step | NANJING UNIVERSITY OF TECHNOLOGY | 2013-12-04 | — | — | CN | disclosed |
| CN-103421012-A | Method for preparing tricarbazole material from aryl indolone in one step | NANJING UNIVERSITY OF TECHNOLOGY | 2013-12-04 | — | — | CN | disclosed |
| EP-1756112-B1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| CN-101541757-A | Pyrazolines as Mineralocorticoid Receptor Antagonists | PFIZER PROD INC (US) | 2009-09-23 | — | — | CN | disclosed |
| WO-1994018194-A1 | OXINDOLE 1-[N-(ALKOXYCARBONYL)]CARBOXAMIDES AND 1-(N-CARBOXAMIDO)CARBOXAMIDES AS INTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0208510-B1 | 1-SUBSTITUTED OXINDOLE-3-CARBOXAMINES AS ANTIINFLAMMATORY AND ANALGESIC AGENTS | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| EP-0175551-B1 | ANALGESIC AND ANTIINFLAMMATORY 1,3-DIACYL-2-OXINDOLE COMPOUNDS | PFIZER INC. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4808601-A | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds | PFIZER INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4791131-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4752609-A | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds | PFIZER INC. (US) | 1988-06-21 | — | — | US | disclosed |
| US-4730004-A | INHIBITORS OF CYCLOOXYGENASE AND LIPOXYGENASE | PFIZER INC. (US) | 1988-03-08 | — | — | US | disclosed |
| US-4690943-A | ENZYME INHIBITOR OF CYCLOOXYGENASE AND LIPOXYGENASE | PFIZER INC. (US) | 1987-09-01 | — | — | US | disclosed |
| EP-0208510-A2 | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| EP-0175551-A1 | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152960-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | HTR7 3859/4885HTR1A 3508/4885DRD2 4721/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | HTR7 3859/4885HTR1A 3508/4885DRD2 4721/4885 |
| US-11034680-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | HTR7 3859/4885HTR1A 3508/4885DRD2 4721/4885 |
| US-20210309647-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | HTR7 3859/4885HTR1A 3508/4885DRD2 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.